EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG

Ryuta Saito iD, Masayuki Kanamori, Yoshiki Arakawa iD, Yohei Mineharu, Yasuo Aihara, Kentaro Chiba, Toshihiro Kumabe, Ichiyo Shibahara, Yukihiko Sonoda, Kenichiro Matsuda, Manabu Kinoshita, Aya Sato und 2 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70054 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Science, 2025. Verfasst von Ryuta Saito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Brain Stem Neoplasms, Diffuse Intrinsic Pontine Glioma, Nimustine, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse intrinsic pontine glioma (DIPG) is a very challenging‐to‐treat pediatric malignant tumor, with a median survival time of < 12 months. Convection‐enhanced delivery (CED) allows for direct drug administration into the tumor site, showing potential as a novel therapeutic approach. This study evaluated the efficacy of CED of nimustine hydrochloride (ACNU) in children with DIPG. This phase 2, single‐arm, multicenter study enrolled patients aged 3–21 years and diagnosed with DIPG. The investigational treatment commenced 1 month after completing radiotherapy (local 50–60 Gy). The treatment involved stereotactic brain surgery for catheter placement, followed by ACNU administration via a CED catheter at a concentration of 0.75 mg/mL for 2–3 days until a cumulative dose of 7 (±0.3) mL was achieved. The primary endpoint was the 1‐year survival rate. From April 2018 to March 2020, 21 children were enrolled in the trial and treated, with 20 evaluable for the primary endpoint. The 1‐year survival rate from the start of radiotherapy was 60%, and the median survival time was 15 months. The response rate was analyzed in 20 patients, with one complete response (CR), six partial responses (PR), nine stable diseases, and four progressive diseases, resulting in a response rate of 35% (CR + PR). The CED of ACNU in the brainstem of children with DIPG after radiotherapy appears to be an effective therapeutic strategy. This approach warrants further development as a treatment for children with DIPG. This study is registered with jRCT (No. jRCT2021190003).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain Stem NeoplasmsDiffuse Intrinsic Pontine GliomaNimustineAntineoplastic AgentsHumansChildFemaleMaleChild, PreschoolAdolescentYoung AdultConvectionTreatment OutcomeDrug Delivery SystemsSurvival Rate

Stichwörter der Autor:innen

convection‐enhanced deliverydiffuse intrinsic pontine gliomalocal chemotherapynimustine hydrochloridephase II investigator‐initiated clinical trial

Substanzen

NimustineAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Department of Neurosurgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
  • Department of Neurosurgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.
  • Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.

ORCID-Profile: Ryuta Saito, Yoshiki Arakawa

Förderung

  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Saito, R., Kanamori, M., Arakawa, Y., Mineharu, Y., Aihara, Y., Chiba, K., Kumabe, T., Shibahara, I., Sonoda, Y., Matsuda, K., Kinoshita, M., Sato, A., Takahashi, F., & Tominaga, T. (2025). A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG. Cancer Science. https://doi.org/10.1111/cas.70054

Vancouver

Saito R, Kanamori M, Arakawa Y, Mineharu Y, Aihara Y, Chiba K, et al. A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG. Cancer Science. 2025. doi:10.1111/cas.70054

BibTeX
@article{Saito2025,
  author = {Saito, Ryuta and Kanamori, Masayuki and Arakawa, Yoshiki and Mineharu, Yohei and Aihara, Yasuo and Chiba, Kentaro and Kumabe, Toshihiro and Shibahara, Ichiyo and Sonoda, Yukihiko and Matsuda, Kenichiro and Kinoshita, Manabu and Sato, Aya and Takahashi, Fumiaki and Tominaga, Teiji},
  title = {A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70054}
}
Kostenlos starten →